A stronger role for science

Nature Reviews Drug Discovery

Volumn 10, Issue 3, 2011, Pages 159-

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; TORCETRAPIB;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; EDITORIAL; HUMAN; HYPERTENSION; INVESTMENT; PRIORITY JOURNAL; RISK REDUCTION;

ANTICHOLESTEREMIC AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; DECISION MAKING; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; QUINOLINES; RESEARCH;

EID: 79952155299     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3387     Document Type: Editorial

References (4)

1. Paul, S. M. et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nature Rev. Drug Discov. 9, 203-214 (2010).
2. Arrowsmith, J. Phase III and submission failures: 2007-2010. Nature Rev. Drug Discov. 10, 87 (2011).
3. Ocana, A. & Tannock, I. F. When are "positive" clinical trials in oncology truly positive? J. Natl Cancer Inst. 103, 16-20 (2011).
4. Fiorino, T. Industry, clinical trials and the cost of cancer drugs: an investor's perspective. J. Clin. Oncol. 25, e21-e23 (2007).